Gilead Sciences (GILD) Operating Expenses (2009 - 2026)

Gilead Sciences (GILD) has reported Operating Expenses for 18 consecutive years, with $18.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 294.9% year-over-year to $18.2 billion; the trailing twelve-month figure through Jun 2026 stood at $33.0 billion (up 58.34% YoY), and the FY2025 full-year result was $19.4 billion, down 28.31% from the prior year.
• Operating Expenses improved to $18.2 billion in Q2 2026 per GILD's latest filing, from $4.4 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $18.2 billion in Q2 2026 and bottomed at $4.2 billion in Q3 2022.
• Historically, Operating Expenses has averaged $6.0 billion across 5 years, with a median of $4.8 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses plunged 59.76% in 2025, then jumped 294.9% in 2026.
• Over 5 years, Operating Expenses stood at $5.1 billion in 2022, then increased by 7.42% to $5.5 billion in 2023, then retreated by 7.0% to $5.1 billion in 2024, then gained by 16.1% to $5.9 billion in 2025, then soared by 206.3% to $18.2 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $18.2 billion, $4.4 billion, and $5.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.